Status: Recruiting
Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels
A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia.
Participants needed: 36
Trial details
Phase: Phase 2Age: 0-11Biological sex: AllType: InterventionalSponsor: Vifor Pharma, Inc.Updated: Sep 25, 2026Locations: 37
Eligibility criteria
Paediatric participants (<12 years of age) with hyperkalaemia at screening. [+12]
Preterm birth infants with <37 weeks of gestation cannot be included in Cohort 3... [+20]